Blood collector Vitalant reported on Thursday a critical shortage of blood as supplies have been significantly impacted by the COVID-19 pandemic.
Since early March, shelter-in-place orders have resulted in a loss of 150,000 uncollected blood donations, while the resumption of surgeries and other medical procedures have caused a 25% increase in the need for blood in the past several weeks.
Calling on donors to alleviate the shortage, Vitalant said that all blood types are critically needed right now, with an especially high need for type O, A-negative and B-negative red blood cells. In addition, platelets are always needed by patients for cancer treatments, surgeries and emergencies. Because of a short shelf life of just five days, the supply of platelets must be continually replenished.
Biovica secures European patent for biomarker use in immuno-oncology
CARsgen Therapeutics' satri-cel NDA accepted by Chinese regulator
Scancell expands Phase 2 SCOPE trial with new intradermal dosing arm for iSCIB1+
Telix Pharmaceuticals delivers first commercial doses from Belgian manufacturing hub
Innovent presents mazdutide Phase 3 clinical study results at ADA 85th Scientific Sessions
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Aiforia Technologies launches CE-IVD marked AI solution for breast cancer diagnostics
Stockholders approve proposed merger of TuHURA Biosciences and Kineta
Sarclisa recommended for EU approval in newly diagnosed transplant-eligible multiple myeloma
Harbour BioMed and Otsuka collaborate on advancing BCMAxCD3 bispecific T-cell engagers
Dizal completes enrolment in sunvozertinib vs. platinum doublet phase III study
RyboDyn joins Lilly Gateway Labs' innovation hub
GRAIL reports positive results from Galleri multi-cancer early detection test registrational study